Patents Assigned to AstraZeneca
  • Benzyl Amines, A Process For Their Production And Their Use As Anti-Inflammtory Agents
    Publication number: 20120289510
    Abstract: The present invention relates to the compounds of formula I, processes for their production and their use as anti-inflammatory agents.
    Type: Application
    Filed: May 7, 2012
    Publication date: November 15, 2012
    Applicants: AstraZeneca AB, Bayer Pharma AG
    Inventors: Markus Berger, Jan Dahmen, Hartmut Rehwinkel, Stefan Jaroch, Heike Schäcke
  • (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES
    Publication number: 20120289513
    Abstract: The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.
    Type: Application
    Filed: July 25, 2012
    Publication date: November 15, 2012
    Applicant: ASTRAZENECA AB
    Inventors: John Cumming, Alan Wellington Faull, David Waterson
  • Benzoimidazole Compounds and Uses Thereof
    Publication number: 20120289504
    Abstract: This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 15, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Louis-David Cantin, Xuehong Luo, Miroslaw Jerzy Tomaszewski
  • CHEMICAL COMPOUNDS 785
    Publication number: 20120289520
    Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity
    Type: Application
    Filed: April 25, 2012
    Publication date: November 15, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Alan Martin Birch, Roger John Butlin, Leonie Campbell, Clive Green, Andrew Leach, Michael James Waring, Paul Michael Murray, Per Olof Ryberg
  • BILAYER TABLET FORMULATIONS
    Publication number: 20120282336
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Application
    Filed: November 12, 2010
    Publication date: November 8, 2012
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
  • Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
    Patent number: 8304417
    Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: November 6, 2012
    Assignee: AstraZeneca AB
    Inventors: James Gair Ford, James Francis McCabe, Anne O'Kearney-McMullan, Simon Mark Pointon, Lyn Powell, Philip O'Keefe, Mark Purdie, Jane Withnall
  • Preparation of Aminopyrimidine Compounds
    Publication number: 20120277432
    Abstract: A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.
    Type: Application
    Filed: June 14, 2012
    Publication date: November 1, 2012
    Applicant: ASTRAZENECA UK LTD.
    Inventors: Akio Matsushita, Mizuho Oda, Yasuhiro Kawachi, Jun-ichi Chika
  • Ethanamine Compounds and Methods of Using the Same
    Publication number: 20120277272
    Abstract: (S)-2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, uses of said compound or salt for therapy of depression and other conditions, and methods of treating depression and other conditions by administering said compound or salt.
    Type: Application
    Filed: March 27, 2012
    Publication date: November 1, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P. McCauley, Lihong Shen, David Nugiel
  • Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
    Patent number: 8299076
    Abstract: Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: October 30, 2012
    Assignees: Array Biopharma Inc., Astrazeneca AB
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, Jim Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
  • N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses
    Patent number: 8299246
    Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: October 30, 2012
    Assignee: AstraZeneca AB
    Inventors: Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
  • NOVEL SALT 628
    Publication number: 20120269872
    Abstract: 6-M ethyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.
    Type: Application
    Filed: June 27, 2012
    Publication date: October 25, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Lars-Erik BRIGGNER, Per Thomas KLINGSTEDT, Hans Roland LÖNN, Robert ZUBAN, Marie-Lyne ALCARAZ, Robert Anthony NIXON, Andrew James WATTS
  • Quinazoline compounds
    Patent number: 8293902
    Abstract: The invention relates to compounds of the formula (I) wherein ring C, Z, m, n, R1 and R2 are defined herein and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: October 23, 2012
    Assignee: AstraZeneca AB
    Inventor: Laurent Francois Andre Hennequin
  • Heterocyclic Compounds as CCR2 Antagonists
    Publication number: 20120264762
    Abstract: Compounds of formula (I) Q-L-W—C(?X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.
    Type: Application
    Filed: June 7, 2012
    Publication date: October 18, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Justin Fairfield Bower, Jeffrey Philip Poyser, Paul Turner, David Waterson, Jon Winter
  • CHROMENONE DERIVATIVES
    Publication number: 20120264731
    Abstract: The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: April 11, 2012
    Publication date: October 18, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie Paul LAMBERT-VAN DER BREMPT, Jean-Jacques Marcel LOHMANN, Patrick PLE
  • Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits
    Publication number: 20120264943
    Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.
    Type: Application
    Filed: June 4, 2012
    Publication date: October 18, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Seth Björk, Vern Delisser, Peter Johnström, Nils Anders Nilsson, Katinka Ruda, Per Magnus Schou, Britt-Marie Swahn
  • Heterocyclic urea derivatives and methods of use thereof
    Patent number: 8283361
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 9, 2012
    Assignee: AstraZeneca AB
    Inventors: Allison Laura Choy, Pamela Hill, John Irvin Manchester, Brian Sherer
  • Combination Therapy
    Publication number: 20120252826
    Abstract: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises: the administration of ZD6474 in combination with 5-FU; ZD6474 in combination with CPT-11; or ZD6474 in combination with 5-FU and CPT-11.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 4, 2012
    Applicant: AstraZeneca AB
    Inventors: Stephen Robert Wedge, Anderson Joseph Ryan
  • Processes for the preparation of optically active intermediates
    Patent number: 8278475
    Abstract: This invention relates to processes for the production of optically active 2-(disubstituted aryl)cyclopropylamine compounds and optically active 2-(disubstituted aryl) cyclopropane carboxamide compounds which are useful intermediates for the preparation of pharmaceutical agents, and in particular the compound [1S-(1?,2?,3?(1S*,2R*),5?]-3-[7-[2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: October 2, 2012
    Assignee: AstraZeneca AB
    Inventors: Masaru Mitsuda, Tadashi Moroshima, Kentaro Tsukuya, Kazuhiko Watabe, Masahiko Yamada
  • Packaging
    Patent number: D668949
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: October 16, 2012
    Assignee: Astrazeneca UK Limited
    Inventors: Robert Hipperson, Sebastien Corvez, Mark Kraaijenbrink
  • Inhaler
    Patent number: D670374
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: November 6, 2012
    Assignee: AstraZeneca UK Limited
    Inventors: Kajsa Bobjer, Camilla Lundström, Mårten Rittfeldt, Jonas Svennberg